VentriPoint Diagnostics (CVE:VPT) Reaches New 12-Month Low – Time to Sell?

VentriPoint Diagnostics Ltd. (CVE:VPT – Get Free Report)’s stock price reached a new 52-week low during trading on Friday. The stock traded as low as C$0.07 and last traded at C$0.08, with a volume of 259,484 shares. The stock had previously closed at C$0.08.

VentriPoint Diagnostics Stock Performance

The firm has a market cap of C$15.43 million, a PE ratio of -4.00 and a beta of -1.07. The company has a quick ratio of 6.67, a current ratio of 0.12 and a debt-to-equity ratio of -68.25. The stock’s fifty day simple moving average is C$0.09 and its two-hundred day simple moving average is C$0.11.

About VentriPoint Diagnostics

(Get Free Report)

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients.

Read More

Receive News & Ratings for VentriPoint Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VentriPoint Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.